ValuEngine upgraded shares of Syros Pharmaceuticals (NASDAQ:SYRS) from a sell rating to a hold rating in a report issued on Wednesday.
A number of other equities analysts have also issued reports on SYRS. BidaskClub raised Syros Pharmaceuticals from a strong sell rating to a sell rating in a research note on Thursday, March 1st. Wedbush reaffirmed an outperform rating and set a $13.00 price target (up from $11.00) on shares of Syros Pharmaceuticals in a research note on Tuesday, March 13th. HC Wainwright reaffirmed a hold rating and set a $10.00 price target on shares of Syros Pharmaceuticals in a research note on Wednesday, March 14th. Cann reiterated a buy rating and set a $28.00 price objective on shares of Syros Pharmaceuticals in a research report on Thursday, May 10th. Finally, Zacks Investment Research downgraded Syros Pharmaceuticals from a hold rating to a sell rating in a research report on Wednesday, May 16th. One research analyst has rated the stock with a sell rating, four have given a hold rating and six have issued a buy rating to the stock. Syros Pharmaceuticals currently has a consensus rating of Hold and a consensus target price of $21.13.
Shares of NASDAQ SYRS opened at $12.50 on Wednesday. The firm has a market cap of $417.98 million, a price-to-earnings ratio of -5.87 and a beta of -2.69. Syros Pharmaceuticals has a 1 year low of $6.30 and a 1 year high of $24.38.
Syros Pharmaceuticals (NASDAQ:SYRS) last issued its quarterly earnings results on Monday, March 12th. The company reported ($0.58) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.57) by ($0.01). equities research analysts predict that Syros Pharmaceuticals will post -2.2 earnings per share for the current year.
Large investors have recently made changes to their positions in the company. Two Sigma Advisers LP acquired a new stake in shares of Syros Pharmaceuticals during the 4th quarter valued at $105,000. Adalta Capital Management LLC acquired a new stake in shares of Syros Pharmaceuticals during the 4th quarter valued at $111,000. The Manufacturers Life Insurance Company lifted its position in shares of Syros Pharmaceuticals by 299.9% during the 1st quarter. The Manufacturers Life Insurance Company now owns 12,922 shares of the company’s stock valued at $168,000 after acquiring an additional 9,691 shares during the last quarter. Virtu Financial LLC purchased a new stake in shares of Syros Pharmaceuticals in the fourth quarter valued at $191,000. Finally, Two Sigma Investments LP lifted its holdings in shares of Syros Pharmaceuticals by 80.3% in the fourth quarter. Two Sigma Investments LP now owns 21,197 shares of the company’s stock valued at $206,000 after purchasing an additional 9,439 shares in the last quarter. Institutional investors own 56.84% of the company’s stock.
About Syros Pharmaceuticals
Syros Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development of treatment for cancer and monogenic diseases, and building a pipeline of gene control medicines. Its lead product candidates include SY-1425, a selective retinoic acid receptor alpha agonist, which is in a Phase II clinical trial for genomically defined subsets of patients with acute myeloid leukemia (AML) and myelodysplastic syndrome; and SY-1365, a selective CDK7 inhibitor, which is in a Phase I clinical trial that is used for treating patients with solid tumors and blood cancers, including ovarian cancer, breast cancer, and AML.
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Syros Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Syros Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.